Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Table 3

Comparison of short-term efficacy (n (%)).

Group	n	CR	PR	NC	PD	Total effective rate
CTG	44	25 (56.82%)	16 (36.36%)	2 (4.55%)	1 (2.27%)	93.18% (41/44)
STG	44	19 (43.18%)	14 (31.82%)	7 (15.91%)	4 (9.09%)	75.00% (33/44)
X^2						5.436
						<0.05